A Japanese health ministry panel has endorsed two products using iPS cells, paving the way for the world's first practical ...

Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients ...

Sumitomo Dainippon Pharma Co ( (JP:4506)) just unveiled an announcement. Sumitomo Pharma has received conditional and time-limited approval in Japan to manufacture and market AMCHEPRY, an allogeneic ...

Japan has formally approved the world’s first regenerative medical products utilizing induced pluripotent stem (iPS) cells, paving the way for use in patients as early as this summer.

Japan has approved two pioneering stem-cell therapies for the treatment of Parkinson’s disease and severe heart failure, marking a major milestone in ...

Shares of Japan's Sumitomo Pharma fell over 15% on the back of profit-taking after a specialist panel endorsed its iPS cell-based therapy for Parkinson's disease.

A Parkinson's disease treatment based on induced pluripotent stem cells (iPS) has been officially approved in Japan – as announced by ...

Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

Establishing a Stable and Efficient Expansion Workflow for Scalable iPS Cell ManufacturingTokyo and Kyoto, Japan - March 5, 2026 – Terumo Corporation (TSE: 4543) and the CiRA Foundation, a public ...

HOUSTON--(BUSINESS WIRE)--IPS HEART has been awarded Orphan Drug Designation (ODD) by the FDA for GIVI-MPCs based on its unique ability to create new muscle with full length dystrophin in Becker ...

Japan has approved the world’s first stem cell therapy for Parkinson’s disease, offering new hope for millions globally. The treatment uses induced pluripotent stem (iPS) cells to replace damaged ...